The U.S. Supreme Court’s 7-2 decision on June 25 overturned a Missouri jury verdict awarding $1.25 million over Roundup cancer warnings, blocking a major category of “failure-to-warn” claims. The ruling won’t end the broader Roundup litigation, and it does not
On a day when the U.S. Supreme Court dealt a blow to Roundup claims, the question for thousands of people with cancer diagnoses was brutally simple: would the law still treat their warning arguments the same way?
On June 25. the justices sided with Bayer in a case tied to sprawling litigation over the weedkiller Roundup. ruling that plaintiffs cannot sue the company for failing to warn that the product might cause cancer. In practical terms. the Court eliminated one common theory used in lawsuits—claims that Bayer violated state law by not including a cancer warning on Roundup’s label.
The decision came as part of a long, grinding legal fight. It also landed after years of exposure allegations against the company’s herbicide, including claims tied to glyphosate, Roundup’s active ingredient.
In a 7-2 ruling. the Supreme Court overturned a Missouri jury verdict that had awarded $1.25 million to John Durnell. a man who said he developed non-Hodgkin lymphoma after years of exposure to glyphosate in Roundup. The justices agreed with Bayer that plaintiffs cannot argue the company violated U.S. state laws for failing to warn about any cancer risk when the U.S. Environmental Protection Agency has found no such risk and requires warnings on the product’s label.
That EPA position—at the center of the Court’s reasoning—reshapes more than one lawsuit. The decision is part of a larger case landscape where tens of thousands of people have accused Bayer of causing cancer.
Bayer has said decades of studies show Roundup and glyphosate are safe for human use.
The Supreme Court’s ruling does not end the Roundup fight, but it narrows the legal door. It wipes out “failure-to-warn” claims—a category that was included in most Roundup lawsuits and generally considered easier to prove than other legal theories. Those claims are now preempted by federal law.
Most of the litigation Bayer faces involves plaintiffs alleging they developed non-Hodgkin lymphoma and other forms of cancer after using Roundup at home or on the job. Roundup is among the most widely used weedkillers in the United States. and Bayer is facing claims from approximately 65. 000 plaintiffs in U.S. state and federal courts.
The larger lawsuits began in 2015, and they typically include multiple claims. While “failure-to-warn” arguments are out, other theories are still in play.
Plaintiffs have also accused Bayer of negligence and misrepresentation of Roundup’s safety in its marketing. They have alleged the product was defective for its intended purpose. Those claims can continue.
Bayer may try to use the Supreme Court’s ruling as leverage in those remaining cases, arguing that the high court’s reasoning should undercut the rest of the litigation.
The litigation momentum didn’t stop at the Supreme Court. In February—after the Court agreed to hear Bayer’s appeal in Durnell’s case—Bayer announced it had reached a $7.25 billion settlement with attorneys seeking to represent a nationwide class of people who said Roundup exposure caused their cancer.
Bayer described the deal as aimed at resolving most remaining lawsuits, along with potential lawsuits from people who have already been exposed to Roundup and develop cancer in the future.
That proposed settlement gained early traction in March, when a state court judge in Missouri gave an initial green light to the deal. Several people objected, and the judge is set to consider final approval at a future court hearing.
The Supreme Court ruling does not change the settlement’s terms. Bayer said it remains committed to moving forward with the deal it reached in February.
For plaintiffs, timing has turned the legal process into a high-stakes calculation. The plaintiffs were given a June 4 deadline to decide whether to opt out of the settlement and pursue individual cases in court—meaning they had to choose without knowing the Supreme Court’s final decision.
Lawyers who negotiated the settlement said the Supreme Court’s ruling vindicates their decision to make a deal and lock in funds for cancer victims before the ruling came from the high court.
For now. the landscape is clear about one thing: the Court’s decision removes a widely used route for plaintiffs to argue they should have received cancer warnings on Roundup’s label. But it leaves the broader litigation standing—alongside a proposed settlement that companies and cancer victims alike have been trying to navigate through as the courts move step by step toward final answers.
Bayer Roundup glyphosate non-Hodgkin lymphoma Supreme Court Missouri jury verdict $1.25 million $7.25 billion settlement failure-to-warn EPA labeling 65 000 plaintiffs class action